Literature DB >> 31449794

Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells.

Amrisha Verma1, Ping Zhu1, Annette de Kloet2, Eric Krause3, Colin Sumners2, Qiuhong Li4.   

Abstract

The renin-angiotensin system (RAS) plays a vital role in cardiovascular physiology and body homeostasis. In addition to circulating RAS, a local RAS exists in the retina. Dysfunction of local RAS, resulting in increased levels of Angiotensin II (Ang II) and activation of AT1R-mediated signaling pathways, contributes to tissue pathophysiology and end-organ damage. Activation of AT2R on other hand is known to counteract the effects of AT1R activation and produce anti-inflammatory and anti-oxidative effects. We examined the expression of angiotensin receptors in the retina by using transgenic dual reporter mice and by real-time RT-PCR. We further evaluated the effects of C21, a selective agonist of AT2R, in reducing Ang II, lipopolysaccharide (LPS) and hydrogen peroxide induced oxidative stress and inflammatory responses in cultured human ARPE-19 cells. We showed that both AT1Ra and AT2R positive cells are detected in different cell types of the eye, including the RPE/choroid complex, ciliary body/iris, and neural retina. AT1Ra is more abundantly expressed than AT2R in mouse retina, consistent with previous reports. In the neural retina, AT1Ra are also detected in photoreceptors whereas AT2R are mostly expressed in the inner retinal neurons and RGCs. In cultured human RPE cells, activation of AT2R with C21 significantly blocked Ang II, LPS and hydrogen peroxide -induced NF-κB activation and inflammatory cytokine expression; Ang II and hydrogen peroxide-induced reactive oxygen species (ROS) production and MG132-induced apoptosis, comparable to the effects of Angiotensin-(1-7) (Ang-(1-7)), another protective component of the RAS, although C21 is more potent in reducing some of the effects induced by Ang II, whereas Ang-(1-7) is more effective in reducing some of the LPS and hydrogen peroxide-induced effects. These results suggest that activation of AT2R may represent a new therapeutic approach for retinal diseases.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AT2R; Angiotensin II; C21; Renin angiotensin system; Retina

Mesh:

Substances:

Year:  2019        PMID: 31449794      PMCID: PMC6759374          DOI: 10.1016/j.exer.2019.107770

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  75 in total

Review 1.  The retinal renin-angiotensin system: roles of angiotensin II and aldosterone.

Authors:  Jennifer L Wilkinson-Berka; Alex Agrotis; Devy Deliyanti
Journal:  Peptides       Date:  2012-04-17       Impact factor: 3.750

2.  ARPE-19, a human retinal pigment epithelial cell line with differentiated properties.

Authors:  K C Dunn; A E Aotaki-Keen; F R Putkey; L M Hjelmeland
Journal:  Exp Eye Res       Date:  1996-02       Impact factor: 3.467

3.  The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature.

Authors:  Erica L Fletcher; Joanna A Phipps; Michelle M Ward; Kirstan A Vessey; Jennifer L Wilkinson-Berka
Journal:  Prog Retin Eye Res       Date:  2010-04-07       Impact factor: 21.198

4.  Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice.

Authors:  James M Dominguez; Ping Hu; Sergio Caballero; Leni Moldovan; Amrisha Verma; Gavin Y Oudit; Qiuhong Li; Maria B Grant
Journal:  Am J Pathol       Date:  2016-05-10       Impact factor: 4.307

Review 5.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

6.  Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Authors:  Nish Chaturvedi; Massimo Porta; Ronald Klein; Trevor Orchard; John Fuller; Hans Henrik Parving; Rudy Bilous; Anne Katrin Sjølie
Journal:  Lancet       Date:  2008-09-25       Impact factor: 79.321

Review 7.  Update on tissue renin-angiotensin systems.

Authors:  Michael Bader; Detlev Ganten
Journal:  J Mol Med (Berl)       Date:  2008-04-15       Impact factor: 4.599

8.  Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy.

Authors:  A H Danser; M A van den Dorpel; J Deinum; F H Derkx; A A Franken; E Peperkamp; P T de Jong; M A Schalekamp
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

9.  The expression of Mas-receptor of the renin-angiotensin system in the human eye.

Authors:  A Vaajanen; G Kalesnykas; H Vapaatalo; H Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-14       Impact factor: 3.117

Review 10.  The renin-angiotensin system: going beyond the classical paradigms.

Authors:  Robson Augusto Souza Santos; Gavin Y Oudit; Thiago Verano-Braga; Giovanni Canta; Ulrike Muscha Steckelings; Michael Bader
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

View more
  3 in total

Review 1.  Emerging Role of Angiotensin AT2 Receptor in Anti-Inflammation: An Update.

Authors:  Sanket N Patel; Naureen Fatima; Riyasat Ali; Tahir Hussain
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

Review 2.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 3.  Relevance of Peptide Homeostasis in Metabolic Retinal Degenerative Disorders: Curative Potential in Genetically Modified Mice.

Authors:  Etelka Pöstyéni; Alma Ganczer; Andrea Kovács-Valasek; Robert Gabriel
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.